23 Trials found, please click on a trial for more information
Protocol Title
Protocol Number / Cancer Type
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
Offered at: Providence Cancer Institute
B-42 / Breast Cancer
A double-blind phase III trial of doxorubicin and cyclophosphamide followed by paclitaxel with bevacizumab or placebo in patients with lymph node positive and high risk lymp node negative breast cancer.
Offered at: Providence Cancer Institute
E5103 / Breast Cancer
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
Offered at: Providence Cancer Institute
N063D/ALTTO/BIG2-06 / Breast Cancer
A randomized phase III double-blind placebo controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER-2/NEU over-expressing metastatic breast cancer
Offered at: Providence Cancer Institute
E1105 / Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0,I or II Breast Cancer
Offered at: Providence Cancer Institute
NSABP B-39 / Breast Cancer
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
Offered at: Providence Cancer Institute
B-40 / Breast Cancer
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Offered at: Providence Cancer Institute
S0500 / Breast Cancer
PHASE III RANDOMIZED TRIAL OF ANASTROZOLE VERSUS ANASTROZOLE AND FULVESTRANT AS FIRST LINE THERAPY FOR POST MENOPAUSAL WOMEN WITH METASTATIC BREAST CANCER
Offered at: Providence Cancer Institute
S0226 / Breast Cancer
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High -Risk Node Negative Breast Cancer
Offered at: Providence Cancer Institute
S0221 / Breast Cancer
Program for the Assessment of Clinical Cancer Tests (PACCT-1)
Offered at: Providence Cancer Institute
TAILORx / Breast Cancer
A Phase II Trial to Evaluate Brachytherapy as the Sole Method of Radiation Therapy for Early Breast Cancer
Offered at: Van Elslander Cancer Center
SJHMC / Breast Cancer
A Phase III Study of Regional Radiation Therapy in Early Breast Cancer
Offered at: Van Elslander Cancer Center
CTSU MA.20 / Breast Cancer
A Phase III Trial Evaluating the Role of Ovarian Function Supression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)
Offered at: Van Elslander Cancer Center
CTSU 24-02 / Breast Cancer
A Phase III Trial of Observatiion +/- Tamoxifen vs. Radiation Therapy +/- Tamoxifen for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast
Offered at: Van Elslander Cancer Center
RTOG 98-04 / Breast Cancer
A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) plus ZD 1839 (Iresa, NSC #715055, IND#61187) and of Combination Fulvestrant (NSC #719276) plus ZD 1839 in the Treatment of Postmene
Offered at: Van Elslander Cancer Center
EST E4101 / Breast Cancer
A randomized Phase III trial of paclitaxel versus paclitaxel plus Bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer.
E 2100(CTSU) / Breast Cancer
Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) vs. Paclitaxel (12 weeks vs. 18 weeks) as Adjuvant Therapy for Womenwith Node-Negative Breast Cancer: A 2X2 Factorial Phase III Randomized Study.
Offered at: Van Elslander Cancer Center
NCCTG 40101 / Breast Cancer
Phase II Study of OSI-774 (Tarceva)+Gemcitabine for Patients with Metastatic Breast Cancer
Offered at: Van Elslander Cancer Center
NCCTG N0234 / Breast Cancer
Phase III Trial of Doxorubicin Cyclophosphamide (AC) followed by weekly Paclitaxel with or without Trastuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing Node Positive Breast Cancer
Offered at: Van Elslander Cancer Center
NCCTG N9831 / Breast Cancer
Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate (Actonel) for Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Carcinoma
Offered at: Van Elslander Cancer Center
NCCTG N02C1 / Breast Cancer
Reflexology: An Intervention for Advanced Breast Cancer
Offered at: Webber Cancer Center
SJ 0807-06 / Breast Cancer
The Use of Ginkgo Biloba for the Prevention of Chemotherapy-Related Cognitive Dysfunction
Offered at: Van Elslander Cancer Center
NCCTG N00C9 / Breast Cancer
Treatment of Chemotherapy-Induced Nausea with Acupressure: A Phase III Trial in Woman Treated for Breast Cancer
Offered at: Van Elslander Cancer Center
MDA 01-09 / Breast Cancer
